logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8952028 B1

PDFFull Text
Date of Patent:
Feb. 10, 2015

Filed:

Feb. 05, 2008

Methods of treating chemoresistance and relapse in cancer cells

Applicant:

Wenyong Chen, Temple City, CA (US);

Inventor:

Wenyong Chen, Temple City, CA (US);

Assignee:

City of Hope, Duarte, CA (US);

Attorneys:

Perkins Coie LLP

Courtney Prochnow

Primary Examiner:

Sarah Pihonak

Int. Cl.
CPC ...
A01N 43/54 (2006.01); A61K 31/505 (2006.01); C07D 239/02 (2006.01); A61K 31/366 (2006.01); A61K 31/05 (2006.01); A61K 31/404 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/366 (2013.01); A61K 31/05 (2013.01); A61K 31/404 (2013.01); A61K 31/7105 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); G01N 33/5011 (2013.01);
Abstract

Methods of treating or preventing chemoresistance or relapse growth of cancer cells are provided. Methods of treating or preventing resistance to tyrosine kinase based chemotherapeutic treatment in hematologic and solid tumors are provided. BCR-ABL drug resistance in chronic myelogenous leukemia (CML) and models for conducting further study on the same are presented. The methods comprise administering a therapeutically effective amount of one or more SIRTmodulators to the cells or subject in need thereof. The methods may be administered in combination with, prior to or subsequent to chemotherapy or may be administered to counteract the effect of a spontaneous genetic mutation. Methods of using SIRTinhibitors to treat or prevent insulin and transferrin-induced resistance are also presented. A novel cell model to study mechanisms of acquired chemoresistance is also provided.

Find Patent Forward Citations

Chen, Wenyong. (2015). Methods of treating chemoresistance and relapse in cancer cells (U.S. Patent No. 8952028). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/8952028

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…